Skip to content
akaturk Academic measurement

Article detail · 2014 · article

Relapses and disability accumulation in progressive multiple sclerosis

Journal Neurology
ISSN0028-3878
YÖKSİS OpenAlex Open access · bronze SJR Q1 JCR Q1 Top 10%
Year2014
Citations113OpenAlex
Percentile%96.6
FWCI5.461.00 = world average
Scopus (SJR)Q1
WoS (JCR)Q1

Data source split

  • YÖKSİSYÖKSİS article record
  • YÖKSİS venueNeurology
  • Catalog match (ISSN)Neurology
  • OpenAlexOpenAlex enrichment (abstract, citations, topics)

Abstract

OpenAlex English

OBJECTIVE: We examined the effect of relapses-before and after progression onset-on the rate of postprogression disability accrual in a progressive multiple sclerosis (MS) cohort. METHODS: We studied patients with primary progressive MS (n = 322) and bout-onset progressive MS (BOPMS) including single-attack progressive MS (n = 112) and secondary progressive MS (n = 421). The effect of relapses on time to Expanded Disability Status Scale (EDSS) score of 6 was studied using multivariate Cox regression analysis (sex, age at progression, and immunomodulation modeled as covariates). Kaplan-Meier analysis was performed using EDSS 6 as endpoint. RESULTS: Preprogression relapses (hazard ratio [HR]: 1.63; 95% confidence interval [CI]: 1.34-1.98), postprogression relapses (HR: 1.37; 95% CI: 1.11-1.70), female sex (HR: 1.19; 95% CI: 1.00-1.43), and progression onset after age 50 years (HR: 1.47; 95% CI: 1.21-1.78) were associated with shorter time to EDSS 6. Postprogression relapses occurred in 29.5% of secondary progressive MS, 10.7% of single-attack progressive MS, and 3.1% of primary progressive MS. Most occurred within 5 years (91.6%) after progressive disease onset and/or before age 55 (95.2%). Immunomodulation after onset of progressive disease course (HR: 0.64; 95% CI: 0.52-0.78) seemingly lengthened time to EDSS 6 (for BOPMS with ongoing relapses) when analyzed as a dichotomous variable, but not as a time-dependent variable. CONCLUSIONS: Pre- and postprogression relapses accelerate time to severe disability in progressive MS. Continuing immunomodulation for 5 years after the onset of progressive disease or until 55 years of age may be reasonable to consider in patients with BOPMS who have ongoing relapses.

Topics

Citations

OpenAlex cited_by_count. Not a WoS or Scopus citation count; those sources have no separate column here.

113citationsOpenAlex · cited_by_count (cache / database)

10 publications in the local catalog that cite this work (OpenAlex reference match; not the full global list).

  1. 2015 Poor early relapse recovery affects onset of progressive disease course in multiple sclerosisCitations 107 · OpenAlex
  2. 2016 Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosisCitations 58 · OpenAlex
  3. 2020 Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple SclerosisCitations 36 · OpenAlex
  4. 2018 Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple SclerosisCitations 29 · OpenAlex
  5. 2022 Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data networkCitations 18 · OpenAlex
  6. 2023 Disability accrual in primary and secondary progressive multiple sclerosis.Citations 8 · OpenAlex
  7. 2019 Predictors of progression in primary progressive multiple sclerosis in a large Turkish cohortCitations 8 · OpenAlex
  8. 2025 Disease course after pregnancy in women with progressive multiple sclerosis symptomsCitations 2 · OpenAlex
  9. 2022 DETERMINANTS OF DISABILITY IN PROGRESSIVE ONSET MULTIPLE SCLEROSISCitations 0 · OpenAlex
  10. 2020 DETERMINANTS OF DISABILITY IN PROGRESSIVE ONSET MULTIPLE SCLEROSISCitations 0 · OpenAlex

Authors

15
  1. MATEO PAZ SOLDAN 1
  2. MARTINA NOVATNA 2
  3. NUHAD ABOU ZEID 3
  4. NİLÜFER KALE İÇEN 4
  5. MELİH TÜTÜNCÜ İSTANBUL ÜNİVERSİTESİ-CERRAHPAŞA 5
  6. DANIEL CRUSAN 6
  7. J. ELİZABETH ATKINSON 7
  8. AKSEL SİVA 8
  9. MARK KEEGAN 9
  10. ISTVAN PIRKO 10
  11. SEAN PITTOCK 11
  12. CLAUDIA LUCCHINETTI 12
  13. BRAIN WEINSHENKER 13
  14. MOSES RODRIGUEZ 14
  15. ORHUN KANTARCI 15